Cabaletta Bio
CABA
62 hedge funds and large institutions have $36.9M invested in Cabaletta Bio in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 12 closing their positions.
3,196% more call options, than puts
Call options by funds: $923K | Put options by funds: $28K
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
1.93% less ownership
Funds ownership: 75.64% → 73.71% (-1.9%)
6% less funds holding
Funds holding: 66 → 62 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
46% less capital invested
Capital invested by funds: $68.9M → $36.9M (-$32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$1.01M |
| 2 |
O
OrbiMed
New York
|
+$719K |
| 3 |
Millennium Management
New York
|
+$572K |
| 4 |
Renaissance Technologies
New York
|
+$521K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$386K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.79M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.29M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$588K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$579K |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$531K |
CABA Hedge Fund Activity: Q1 2022 in Review
62 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q1 2022, worth a combined $36.9M — down 46% from $68.9M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CABA and 8 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 18 added.
The largest buyer was Samlyn Capital, adding an estimated $1.01M. The largest seller was Great Point Partners, exiting entirely with an estimated $1.79M sold.
- 62 institutional investors held Cabaletta Bio (CABA) as of Q1 2022, down from 66 in Q4 2021.
- Funds reported $36.9M of Cabaletta Bio stock for Q1 2022, down 46% quarter-over-quarter.
- 8 funds opened new Cabaletta Bio positions in Q1 2022 and 12 closed out, a net change of -4 holders.
- The largest Cabaletta Bio buyer in Q1 2022 was Samlyn Capital, an estimated $1.01M added.
- The largest Cabaletta Bio seller in Q1 2022 was Great Point Partners, an estimated $1.79M sold.
Based on aggregated 13F filings for Q1 2022.